Julphar, a leading UAE pharmaceutical company, has agreed to divest selected retail and distribution assets to Al Batha Healthcare Group, aiming to streamline operations and focus on core competencies to enhance growth and shareholder value.

Information on the Target

Gulf Pharmaceutical Industries, commonly known as Julphar, is a leading pharmaceutical company based in Ras Al Khaimah, UAE, recognized for its extensive portfolio of high-quality medications. With a robust presence in the MENA region, Julphar has established itself as a trusted name in the pharmaceutical sector, specializing in a variety of therapeutic areas and consistently striving for innovation and operational excellence.

In its recent financial report for the third quarter of 2025, Julphar demonstrated a solid performance, posting a net revenue of AED 249.7 million, a 5% increase contributing to a year-to-date revenue of AED 796.1 million. The company's continued commitment to improving cost efficiencies and operational discipline has significantly boosted its profitability, showcasing a strategic focus on enhancing shareholder value through consistent growth.

Industry Overview in the UAE

The pharmaceutical industry in the United Arab Emirates has experienced substantial growth in recent years, driven by factors such as increasing healthcare expenditure, a rising population, and a growing demand for innov